---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-023339"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:37:19.245703+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive

## Summary
- Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.
- Narinder P. Bhalla appointed Chief Medical Officer effective Jan 20, 2026, succeeding Eric Adler.
- Eric Adler steps down as executive officer to become CEO of Myoventive, co-founded by Lexeo, Perceptive Xontogeny, and venBio Partners.
- Adler remains senior clinical and scientific advisor to Lexeo.

## SEC filing metadata
- accession: 0001193125-26-023339
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/0001193125-26-023339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/lxeo-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-023339
- JSON: https://secwatch.observer/filing/0001193125-26-023339.json
- Plain text: https://secwatch.observer/filing/0001193125-26-023339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.